Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO 2022 Notebook: Future Directions For R&D

Executive Summary

News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.

You may also be interested in...



Global Cancer Coalition Seeks To Boost Access To Medicines In Lower-Income Countries

The Union for International Cancer Control and its industry and other partners say the Access to Oncology Medicines Coalition will help to facilitate access to cancer drugs in low- and lower-middle-income countries.

Sanofi Tries To ‘Bring More Of The Outside In’ For Diversity Efforts

The company is focusing first on gender parity as it navigates around tricky legal frameworks on collecting demographic data.

Genentech Brings Diversity Commitment To The C-Suite

Scrip

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel